

Prevalence of neurological symptoms in patients with SARS-CoV-2: Systematic Review and Meta-Analysis

Júlio Araújo Rendeiro¹, Cesar Augusto Medeiros Paiva Rodrigues¹, Nathalia Lima Costa¹, Marianne Lucena da Silva², Tatiane Bahia do Vale Silva³, Caroline Prudente Dias⁴, Larissa Salgado de Oliveira Rocha^{4,5}, Rodrigo Santiago Barbosa Rocha⁴, Katiane da Costa Cunha⁴

¹Universidade do Estado do Pará (UEPA) – Marabá (PA), Brazil

²Universidade de Brasília (UnB) – Brasília (DF), Brazil

³Universidade do Estado do Pará (UEPA) – Tucuruí (PA), Brazil

⁴Universidade do Estado do Pará (UEPA) – Belém (PA), Brazil

⁵Centro Universitário do Estado do Pará (CESUPA) – Belém (PA), Brazil

ABSTRACT

Introduction: The novel coronavirus, dubbed SARS-CoV-2, which causes the COVID-19 disease, was detected on December 31, 2019, in Wuhan, China. **Objective:** To perform a systematic review with a meta-analysis about the prevalence of headache and myalgia in patients with SARS-CoV-2. **Methods:** High-sensitivity research was conducted on the main platforms (Medline by PubMed, Embase (Elsevier), and Cochrane Library). The entire versions of the manuscripts were analyzed by three independent researchers, and only observational studies describing the symptoms of the selected sample were included. **Results:** 1,782 studies were identified, which were submitted to exclusion criteria, remaining only 62 manuscripts to do qualitative synthesis and metanalysis. Of the 28,412 patients diagnosed with SARS-CoV-2, 12% (95% CI 9% - 16%) presented headache and 19% (95% CI 14% - 24%) presented myalgia, both with statistical significance and high heterogeneity ($I^2=97.0\%$, $p<0.01$ and $I^2=98.0\%$, $p<0.01$, respectively). **Conclusion:** It was noticed that headache and myalgia were the most ordinary neurological symptoms, but it is important to emphasize the prevalence of symptoms in different degrees of severity of the patients.

Keywords: Covid-19; neurology; Myalgia; Headache.

INTRODUCTION

In December 2019, a viral epidemic was established in Wuhan, China, and the disease agent was identified as a new coronavirus, named SARS-CoV-2. The virus quickly reached several countries around the world, and the World Health Organization (WHO) declared a pandemic in March 2020¹. It is documented that the transmission was primarily in the Huanan seafood market, being later transmitted from person to person, symptomatic or asymptomatic, through aerosols^{2,3}.

Typically, its clinic consists of fever and respiratory symptoms such as dyspnea, cough, and fatigue^{1,4}. It has a wide clinical spectrum, from asymptomatic patients to severe cases with respiratory failure⁴. Some populations are more prone to develop severe cases,

How to cite this article: Rendeiro et al. Prevalence of neurological symptoms in patients with SARS-CoV-2: Systematic Review and Meta-Analysis. ABCS Health Sci. 2024;49:e024308 <https://doi.org/10.7322/abcshs.2023040.2299>

Received: Mai 25, 2023

Revised: Dec 14, 2023

Approved: Jan 15, 2024

Corresponding author: Rodrigo Santiago Barbosa Rocha - Universidade Estadual do Pará - TV. Perebebuí, 2623 – Marco – CEP: 66095-662 – Belém (PA), Brazil - E-mail: rodrigo.santiago.rocha@uepa.br

Declaration of interest: nothing to declare.



This is an open access article distributed under the terms of the Creative Commons Attribution License
© 2024 The authors

such as the elderly and people with comorbidities (hypertension, chronic obstructive pulmonary disease, and diabetes)¹.

Other symptoms are attributed to the neuroinvasive capacity of the COVID-19 virus, although this capacity is little known². This virus's ability to reach the individual's nervous system, although documentation is scarce, can generate mild neurological symptoms (anosmia, myalgia, headache, and hyposmia) and other important neurological symptoms (encephalopathy, Guillain-Barre syndrome, confusion, agitation, and cerebrovascular diseases)^{1,4}. Of these neurological symptoms, is remarkable the prevalence of headache and myalgia among the patients who developed COVID-19 at different levels of severity^{2,5,6}.

Therefore, the objective of this study is to show the prevalence of headache and myalgia caused by SARS-CoV-2 by means of a systematic review and meta-analysis.

METHODS

Search strategy

This study is presented as a systematic review with a meta-analysis of prevalence and is by the recommendations and criteria used in the report items for systematic reviews and meta-analyses (PRISMA) and Cochrane Handbook. The question was: what are the main neurological symptoms in patients with SARS-COV-2?

Data Sources

Potential studies were identified using a comprehensive strategy. Data collection was carried out between January 2020 and December 2021. The systematic review was performed in the databases: PubMed via Medline; EMBASE; Latin American and Caribbean Center on Health Sciences Information (Lilacs); and Cochrane Library (Central). The search strategy involved the crosschecking of keywords selected based on the Medical Subjects Headings (Mesh). There was language restriction for English, Spanish, and Portuguese. The following keywords were used: PubMed via Medline (coronavirus[MeSH Terms]) AND Myalgia; Headache OR coronavirus infections[MeSH Terms] AND Myalgia; Headache OR "betacoronavirus"[MeSH Terms] AND Myalgia; Headache OR "betacoronavirus 1"[MeSH Terms] AND Myalgia; Headache OR (Coronaviruses OR "Coronavirus Infection" OR "COVID-19" OR "Coronavirus Infection Disease 2019" OR "2019 Novel Coronavirus Infection" OR "2019-nCoV Infection" OR "2019 nCoV Infection" OR "2019-nCoV Infections" OR Betacoronavirus* OR "Novel Coronavirus Pneumonia" OR "2019 novel coronavirus" OR "coronavirus disease 2019" OR "nCoV" OR COVID* OR "bat coronavirus") AND Myalgia; Headache.

Embase (Elsevier) ('coronavirus infection'/exp OR 'coronavirus infection' OR 'betacoronavirus'/exp OR betacoronavirus OR 'coronavirus disease 2019'/exp OR 'coronavirus disease 2019')

AND [article]/lim AND [humans]/lim AND [clinical study]/lim AND [embase]/lim AND Myalgia; Headache [article].

Latin American and Caribbean Center on Health Sciences Information (Lilacs) MH:(“Coronavirus Infection”) AND (Myalgia; Headache) OR (“Infecciones por Coronavirus”) AND Myalgia; Headache OR (“Infeções por Coronavirus”) AND (Myalgia; Headache) OR (“Coronavirus Infection”) AND (Myalgia; Headache) OR (“Infection, Coronavirus”) AND (Myalgia; Headache) OR (“Infections, Coronavirus”) AND (Myalgia; Headache) OR “Coronavirus” AND (Myalgia; Headache) OR “Coronavirus” AND (Myalgia; Headache) OR “Coronavirus” AND (Myalgia; Headache) OR “bat coronavirus” AND (Myalgia; Headache) OR MH:C02.782.600.550.200\$ OR MH:B04.820.504.540.150\$.

Cochrane Central (MeSH descriptor: [Coronavirus AND Myalgia; Headache] explode all trees OR MeSH descriptor: [Betacoronavirus AND Myalgia; Headache] explode all trees OR MeSH descriptor: [Coronavirus Infections AND Myalgia; Headache] explode all trees OR Coronavirus* OR betacoronavirus* OR nCoV* OR novel coronavirus* OR novel coronavirus OR COVID* OR “bat coronavirus” AND Myalgia; Headache) After the selection of potentially relevant studies, the full-text versions were analyzed for methodological quality by two researchers independently and disagreement between reviewers was resolved by discussion or arbitration by the other researcher.

Types of studies and participants

The criteria adopted for the selection of the studies were: Cross-sectional studies; neurologic conditions to SARS COV outbreak. Editorials, letters to the editor, viewpoints, case presentations, or brief communication were excluded as they did not contain SARS-CoV-2 with other types of viruses, studies with demographic data only, did not perform symptom analysis, and incomplete manuscripts.

Data extraction

The extensive material obtained by the search was exported to a Mendeley[®] paste and exposed in the PRISMA diagram (Figure 1). The first two screenings (selection by title and abstract) were conducted by three independent researchers (JR, NL, and CR), who performed a selection of potential manuscripts to be included in the systematic review. Regarding data extraction, the three independent researchers (JR, NL, and CR) used a Microsoft Excel[®] extraction file, to catalog: study data (authors, journal name, year of publication, country, and study setting), methodological information (study objective, design, total sample size, neurological symptoms, mean age, sex).

Quality Assessment

It was used the Newcastle–Ottawa scale to assess the quality of the included studies. Relevant organizational websites including the Joanna Briggs Institute publish a Reviewers' Manual, which is

designed to support individuals who are performing systematic reviews following JBI methodologies and methods⁷. This checklist contains 9 questions, divided into 3 domains: participants (questions 1, 2, 4 and 9), outcome measurement (6 and 7), and statistics (3, 5 and 8). A study was rated with high quality when the methods were appropriate in all 3 domains. Quality assessment was also performed by 2 independent reviewers, and any uncertainties were resolved by consulting a third reviewer.

Data analysis

For the prevalence estimates of the included observational studies, a random-effects meta-analysis model was used with the Variance Estimator DerSimonian and Laird, assuming that the effect of interest is the same in all studies and the differences observed between them are due only to sampling errors (variability within the studies). The Freeman-Tukey double arcsine transformation was used to stabilize the variances⁸. The heterogeneity of the estimates of the sample size effect throughout these studies was quantified by the I² statistic. The heterogeneity between the studies was assessed by Cochran's Q test and I² statistics. The estimates of the headache and myalgia were presented in Forest Plot with 95% confidence intervals (95% CI) or Scatter Plots with point estimates and 95% CI. All analyses were performed using R statistical software version 4.0 (R Core Team, 2020), with meta package⁹ version 4.11-0 z.

RESULTS

Selection and evaluation of studies

The initial search identified 1,846 studies with neurological symptoms related to the COVID-19 outbreak. Sixty-two duplicate studies were removed which resulted in a total of 1,784 studies. After title and abstract analysis, 1,687 ineligible studies were excluded based on inclusion criteria (Figure 1).

Included studies.

This systematic included a total of 62 studies¹⁰⁻⁶⁵ (Table 1). Among the included studies, 50 were from China, 4 from Italy, 3 from the USA, 1 from France, 1 from Germany, 1 from South Korea, 1 from Japan, and 1 from the UK. The total population corresponded to 25,117 participants, with 7,027 healthcare workers, 16,203 general population, and 1,887 patients with SARS-CoV-2. Most of the respondents had >18 years and approximately 7,789 were male (some studies were unclear).

Prevalence of headache and myalgia

The Forest Plot in Figure 2 shows that the prevalence of headache was 12% (95% CI 9% - 16%) of the 28,412 patients diagnosed with SARS-CoV-2, with statistical significance and high heterogeneity (I²=97.0 %, p=0). The lowest prevalence of headaches was




Figure 1: Study Flow Diagram - PRISMA 2009 Flow Diagram

Table 1: Study characteristics of studies included with country, age, sample, myalgia, and headache number of cases.

Authors	Country	Age	Sample Characteristics	Myalgia (n)	Headache (n)
Giacomelli et al. ¹⁰	Italy	18-95	161 men (122 Sv-39 Mr) 72 women (63 Sv-9 Mr), 17 deaths	12	12
Wei et al. ⁴	China	36±6	Health care workers	14	8
Han et al. ¹¹	China	0.2-70	Children (7) Adult (25)	13	n
Lei et al. ¹²	China	21-82	Men (77) and Women (42); Admission to ICU (1)	18	n
Yang et al. ⁵	China	41.22 ± 17.549 vs 59.97 ± 14.126	72 men (33 mild symptoms, 40 severe); 61 women (33 mild symptoms-28 severe); Mild symptoms-smoking (58 men-7 women); severe symptoms (61 men-7 women)	115	124
Ma et al. ¹³	China	<16	4 asymptomatic, 10 very mild, 108 mild, 4 severe	4	n
Shi et al. ¹	China	59.38±16.54	104 (64.60%) males and 57 (35.40%) females	n	5
Liu et al. ¹⁴	China	46.2 ± 15.9	39 men-33 women; No complication (3), mild (61), severe (8)	n	4
Zhang et al. ¹⁵	China	56-70	138 men (38 with diabetes mellitus -100 without diabetes mellitus); 120 women (25 with diabetes mellitus; 95 without diabetes mellitus)	40	28
Shabto et al. ¹⁶	USA	30-94	Men (13)- Women (36)	n	18
Sun et al. ¹⁷	China	47	8 patients had mild disease, 36 had moderate disease (57.1%), 10 were severe (15.9%), 9 were critically ill (14.3%)	16	8
Tian et al. ¹⁸	China	47.5	Severe disease- 46, Common and mild- 216// 127 men and 135 women	n	17
Ji et al. ¹⁹	China	37–61	53 women, and 48 men//5 smokers	16	6
Zhou et al. ²⁰	China	66.10±;13.94	13 men, 8 women//8 (38.1%) severe and 13 (61.9%) critical; Never smoked (15) Smoker (6)	2	n
Lechien et al. ²	France	39.17±12.09	Mild to moderate patients/ 436 health professionals	887	998
Chen et al. ²¹	China	50.0–65.0	Moderate: 10; Severe: 11	8	2
Shang et al. ²²	China	46 ± 33.55	Patients with pneumonia by covid-19	39	22
Chen et al. ²³	China	26-40	Pregnant in the 3rd trimester, underwent cesarean, epidemiologically exposed to COVID-19	3	n
Yang et al. ³	China	34-98	Cancer patients	1	3
Lei et al. ²⁴	China	43-63	COVID-19 Patients	11	8
D'Silva et al. ²⁵	USA	62.5	Patients with rheumatic disease: 52; Without rheumatic disease: 104	66	15
Yan et al. ²⁶	China	49-73	Patients with severe COVID-19	n	21
Tian et al. ²⁷	China	44.3±1.67	37 patients (5 -mild, 30- moderate, 1 severe, 1 critically ill)	2	3
Chen et al. ⁶	China	44-70	Patients	60	31
Wang et al. ²⁸	China	42-68	Hospitalized patients (40 health professionals)	48	9
Chen et al. ²⁹	China	47 ± 14.6	Severe patients: 43; no severe: 102	20	24
Zheng et al. ³⁰	China	33.5-57	Severe patients: 30; No severe: 131	18	12
Zhang et al. ³¹	China	33-55	Mild patients: 116; moderates: 25; severe: 12	44	33
Zheng et al. ³²	China	58-73	Patients	5	2
Chu et al. ³³	China	26-7	Hospitalized health professionals. Common type of COVID-19: 11; Severe: 40; Critical: 3	3	n
Kim et al. ³⁴	South Korea	22-47	213 Patients (41-asymptomatic, 172-mild)	54	54
Colaneri et al. ³⁵	Italy	10-94)	Mild Patients: 27; severe: 17	1	n
Guan et al. ³⁶	China	0--65	No severe patients: 926; Severe Patients: 173; 39 Health Care	164	150
Zhang et al. ³⁷	China	56-70	Cancer patients	4	n
Wang et al. ³⁸	China	16-89	138 hospitalized patients	170	152
Niu et al. ³⁹	China	50-80	No severe patients: 93; Severe Patients: 48	n	4
Zhao et al. ⁴⁰	China	22-9	No Severe Patients: 61; Severe Patients: 30	15	n
Yang et al. ⁴¹	China	59.7±13.3	Severe Patients	6	3
Zhou et al. ⁴²	China	18-87	191 hospitalized patients	29	n
Kato et al. ⁴³	Japan	62-71	70 patients positive for SARS-CoV-2	3	6
Peng et al. ⁴⁴	China	51-69	No Severe Patients: 4; Severe Patients: 3; Critical patients: 3	N	6
Xu et al. ⁴⁵	China	35-53	COVID- 19 Patients	4	N
Zhang et al. ⁴⁶	China	39-65.5	No Severe Patients: 166; Severe Patients: 55	N	17
Huang et al. ⁴⁷	China	41-58	Patients outside the ICU: 28; Patients in the ICU: 13	N	17
Sun et al. ⁴⁸	China	34-56	No Severe Patients: 40; Severe Patients: 15	10	6
Liguori et al. ⁴⁹	Italy	55 ± 14.65	No Severe Patients	25	40
Brandstetter et al. ⁵⁰	Germany	18-65	Hospital staff	15	15
Cao et al. ⁵¹	China	26-72	8 COVID-19 patients after discharge	1	n
Zhang et al. ⁵²	China	62.7 ± 14.2	Patients with moderate disease: 30; Patients with severe disease: 100; Patients with critical disease: 36	63	53

It continues...

Table 1: Continuation.

Authors	Country	Age	Sample Characteristics	Myalgia (n)	Headache (n)
He et al. ⁵³	China	34-62	No Severe Patients: 135; Severe Patients: 69	20	14
Yin et al. ⁵⁴	China	27-78	COVID-19 Patients	14	2
Cummings et al. ⁵⁵	USA	≥18	257 patients, critically ill with acute hypoxemic respiratory failure	67	10
Docherty et al. ⁵⁶	UK	>90	Hospital inpatients with COVID-19	4026	1033
Du et al. ⁵⁷	China	0-65	85 fatal cases of COVID-19	14	4
Liu et al. ⁵⁸	China	36-56	COVID-19 pneumonia patients	24	n
To et al. ⁵⁹	China	37-75	COVID-19 Patients	2	n
Wu et al. ⁶⁰	China	46.9	COVID-19 Patients	2	n
Yu et al. ⁶¹	China	65-88	4 Patients with COVID-19	6	3
Zha et al. ⁶²	China	32-54	31 patients infected with SARS-CoV-2	18	4
Qiu et al. ⁶³	China	1-16	Moderate children (19) and mild (17)	n	3
Alberici et al. ⁶⁴	Italy	51-64	20 Patients with pneumonia by SARS-CoV2	5	n
Xu et al. ⁶⁵	China	18-80	50 Patients (mild-9, common- 28, severe- 10, critically severe- 3)	n	5

found in the study of Shi et al.¹, at 4%, and the highest in the study of Lechien et al.² at 70%.

Figure 3 shows the prevalence of myalgia in 19% (95% CI 14% - 24%) of the 28,256 individuals with SARS-VoC-2 investigated, with statistical significance and high heterogeneity ($I^2=98.0\%$, $p<0.01$). The study of Yang et al.³, had the lowest prevalence of 2% and Yang et al.⁵, had the highest prevalence (86%) of myalgia.

The methodological quality of the selected studies

The Newcastle-Ottawa Scale is graduated by a system with stars graduation that goes from 0 to 9 delimited into three domains: selection, comparability, and outcome. The analysis indicated the presence of 7 studies with a high score in this review; such studies demonstrated a defined methodology and high evidence. Considering a maximum score of 10 points, the selected manuscripts varied from 2 to 10 points on the Newcastle-Ottawa Scale (Table 2). Higher scores represent better quality.

The risk assessment of bias using “The Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies” was described in Table 3. It was observed that all studies measured the outcomes validly and reliably and described the study subjects in detail.

DISCUSSION

The main findings of the study reveal the occurrence of neurological symptoms due to Coronavirus infection. In this systematic review with meta-analysis, it was found that 62 studies identified headache and myalgia as the most recurrent neurological manifestations.

Several exposure factors can interfere with the frequency and duration of such symptoms, some factors such as age, gender, and regular physical exercise can influence these characteristics. Patients who have comorbidities, such as diabetes mellitus, systemic arterial hypertension, and chronic obstructive pulmonary disease, are more susceptible to the appearance of symptoms such

as headache and neuromuscular complications such as muscle atrophy, muscle pain, and muscle fatigue^{66,67}.

Although the analyzed studies show a great heterogeneity, because they involve sample sizes and populations with distinct socio-demographic characteristics, in general, the investigations that included health professionals in China and Europe, and the elderly, presented a higher frequency of myalgia and headache^{2,4}. The symptoms disappeared in most of the participants within two weeks after the onset of the disease⁴. Furthermore, was observed the high number of health professionals infected, and a higher frequency of studies originating from China because of the pandemic beginning in this location.

In a European multicenter study, the prevalence of headache and myalgia varied significantly according to age and gender in the evaluation of mild to moderate cases, in which female participants showed a higher frequency of symptoms². In the present review, the generalization of the data was difficult, considering the different investigated populations, sometimes including young patients with less comorbidity, and the exclusion of severe cases due to the impossibility of reporting the investigated symptoms, in some studies.

Such symptoms were listed and considered in the creation and assessment of an early warning model based on risk factors to infer disease severity. There were significant differences in the analysis between mild and severe subgroups when in the presence of comorbidities such as diabetes, cardiovascular diseases, and Chronic Obstructive Pulmonary Disease, with myalgia being the most reported.

This systematic review with meta-analysis shows the simultaneous occurrence of headache and myalgia in 35 studies, 9 investigations with only headache, and 17 with only myalgia. In this regard, it was possible to observe the presence of neurological symptoms of the central nervous system (headache) and skeletal muscle symptoms (myalgia), in most of the studies that had the broader objective of describing the clinical characteristics of patients with COVID-19, according to the classification of mild and moderate.

In studies that included hospitalized patients with the classification of moderate, severe, or critically ill in China, according to the Guidance for Corona Virus Disease 2019 (6th edition) released by the National Health Commission of China, it was observed in the evaluation between recovered and deceased patients, which those who died, the myalgia was one of the least common symptoms, and the incidence of this symptom did not differ significantly among the groups. However, those classified as severe were among the deceased, and the moderate to mild patients were among the recovered²¹.

Prospective studies, which monitored hospitalized individuals, revealed that myalgia was among the most common symptoms reported, and in some cases with also headache^{48,51}. However, it is worth pointing out the presence of limitations resulting from selection bias due to the inclusion of only patients registered in the monitoring programs.

The clinical presentation of COVID-19 has variations in its stages, and the difficulty in finding predictors of disease severity

is a constant. However, the elderly and patients with comorbidities can have a greater risk of developing the disease in severe form⁵². The presence of the symptoms investigated in this review is among the initial ones, mainly myalgia^{12,22}.

Headache, anosmia, ageusia, and myalgia are among the most limiting symptoms resulting from COVID-19, most found in the acute phase, but which can persist during long COVID⁶⁸. In general, headaches are bilateral and occur due to reduced cerebral tissue perfusion, the inflammatory process, and hypoxemia⁶⁹. Another factor that can exacerbate the occurrence of this symptom is the intense inflammatory process that occurs due to the activation of P2X7 receptors, which are related to the worsening of brain diseases in general, such as Parkinson's, Alzheimer's, and depression⁷⁰. Therefore, it is believed that inhibitors of this activation of P2X7 receptors are one of the possibilities to minimize the occurrence of neurological symptoms resulting from COVID-19.




Figure 2: Headache prevalence in the manuscripts that investigated the population with COVID-19.




Figure 3: Myalgia prevalence in the manuscripts that investigated the population with COVID-19.

Table 2: Methodological quality of the studies by Newcastle-Ottawa Scale with data on representativeness of the sample, comparability, and outcome.

Authors	Representativeness of the sample (max 5 *)			Comparability (max 2 *)			Outcome (max 3 *)		Total SCORE (OUT OF 10*)
	Representativeness of the sample (**)	Sample size (*)	Non-respondents (*)	Ascertainment of the exposure (risk factor) (***)	Confounding factors are controlled. (**)	Assessment of the outcome (****)	Statistical test (*)		
Alberici et al. ⁶⁴	*		*	**	*	**		*****	
Brandstetter et al. ⁵⁰	*			**	*	**	*	*****	
Cao et al. ⁵¹	*		*	**	*	**	*	*****	
Chen et al. ²¹	*		*	**	*	**	*	*****	
Chen et al. ²³	*		*	*	*	**		*****	
Chen et al. ⁶	*	*	*	**	*	**	*	*****	
Chen et al. ²⁹	*	*	*	**	*	**	*	*****	
Chu et al. ³³	*		*	**	*	**	*	*****	
Colaneri et al. ³⁵	*		*	*	*	**		*****	

It continues...

Table 2: Continuation.

Representativeness of the sample (max 5 *)				Comparability (max 2 *)			Outcome (max 3 *)	
Authors	Representativeness of the sample (**)	Sample size (*)	Non-respondents (*)	Ascertainment of the exposure (risk factor) (***)	Confounding factors are controlled. (**)	Assessment of the outcome (****)	Statistical test (*)	Total SCORE (OUT OF 10*)
Cummings et al. ⁵⁵	*	*	*	**	*	**	*	*****
Docherty et al. ⁵⁶	*	*	*	**	*	**	*	*****
D'Silva et al. ²⁵	*	*	*	**	*	**	*	*****
Du et al. ⁵⁷	*	*	*	**	*	**	*	*****
Giacomelli et al. ¹⁰	*	*	*	**	*	**	*	*****
Guan et al. ³⁶	*	*	*	**	*	**	*	*****
Han et al. ¹¹	*	*	*	**	*	**	*	*****
He. et al. ⁵³	*	*	*	**	*	**	*	*****
Ji et al. ¹⁹	*	*	*	**	*	**	*	*****
Kato et al. ⁴³	*	*	*	**	*	**	*	*****
Kim et al. ³⁴	*	*	*	**	*	**	*	*****
Lechien et al. ²	*	*	*	**	*	**	*	*****
Lei et al. ¹²	*	*	*	**	*	**	*	*****
Lei et al. ²⁴	*	*	*	**	*	**	*	*****
Liguori et al. ⁴⁹	*	*	*	**	*	**	*	*****
Liu et al. ¹⁴	*	*	*	**	*	**	*	*****
Ma et al. ¹³	*	*	*	**	*	**	*	*****
Shang et al. ²²	*	*	*	**	*	**	*	*****
Sun et al. ¹⁷	*	*	*	**	*	**	*	*****
Sun et al. ⁴⁸	*	*	*	**	*	**	*	*****
Tian et al. ¹⁸	*	*	*	**	*	**	*	*****
Shabto et al. ¹⁶	*	*	*	**	*	**	*	*****
To et al. ⁵⁹	*	*	*	**	*	**	*	*****
Wang et al. ²⁸	*	*	*	**	*	**	*	*****
Wang et al. ³⁸	*	*	*	**	*	**	*	*****
Wei et al. ⁴	*	*	*	**	*	**	*	*****
Wu et al. ⁶⁰	*	*	*	**	*	**	*	*****
Xu et al. ⁴⁵	*	*	*	**	*	**	*	*****
Yang et al. ³	*	*	*	**	*	**	*	*****
Yang et al. ⁵	*	*	*	**	*	**	*	*****
Yang et al. ⁴¹	*	*	*	**	*	**	*	*****
Yin et al. ⁵⁴	*	*	*	**	*	**	*	*****
Yu et al. ⁶¹	*	*	*	**	*	**	*	*****
Zha et al. ⁶²	*	*	*	**	*	**	*	*****
Zhang et al. ¹⁵	*	*	*	**	*	**	*	*****
Zhang et al. ³¹	*	*	*	**	*	**	*	*****
Zhang et al. ³⁷	*	*	*	**	*	**	*	*****
Zhang et al. ⁴⁶	*	*	*	**	*	**	*	*****
Zhao et al. ⁴⁰	*	*	*	**	*	**	*	*****
Zheng et al. ³⁰	*	*	*	**	*	**	*	*****
Zheng et al. ³²	*	*	*	**	*	**	*	*****
Zhou et al. ⁴²	*	*	*	**	*	**	*	*****
Zhou et al. ²⁰	*	*	*	**	*	**	*	*****
Xu et al. ⁶⁵	*	*	*	**	*	**	*	*****
Huang et al. ⁴⁷	*	*	*	**	*	**	*	*****
Zhang et al. ⁴⁶	*	*	*	**	*	**	*	*****
Liu et al. ⁵⁸	*	*	*	**	*	**	*	*****
Niu et al. ³⁹	*	*	*	**	*	**	*	*****
Peng et al. ⁴⁴	*	*	*	**	*	**	*	*****
Qiu et al. ⁶³	*	*	*	**	*	**	*	*****
Shabto et al. ¹⁶	*	*	*	**	*	**	*	*****
Shi et al. ¹	*	*	*	**	*	**	*	*****
Tian et al. ²⁷	*	*	*	**	*	**	*	*****
Yan et al. ²⁶	*	*	*	**	*	**	*	*****

Table 3: Study bias risk included according to JBI Critical Appraisal Checklist for Analytical Cross-Sectional Studies.

Authors	Were the criteria for inclusion in the sample clearly defined?	Were the study subjects and the setting described in detail?	Was the exposure measured validly and reliably?	Were objective, standard criteria used for measurement of the condition?	Were confounding factors identified?	Were strategies to deal with confounding factors stated?	Were the outcomes measured validly and reliably?	Was appropriate statistical analysis used?
Alberici et al. ⁶⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear
Brandstetter et al. ⁵⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Cao et al. ⁵¹	No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear
Chen et al. ²¹	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chen et al. ²³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear
Chen et al. ⁶	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chen et al. ²⁹	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chu et al. ³³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Colaneri et al. ³⁵	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Unclear
Cummings et al. ⁵⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Docherty et al. ⁵⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
D'Silva et al. ²⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Du et al. ⁵⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear
Giacomelli et al. ¹⁰	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Guan et al. ³⁶	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Han et al. ¹¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
He et al. ⁵³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ji et al. ¹⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kato et al. ⁴³	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kim et al. ³⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear
Lechien et al. ²	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lei et al. ¹²	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lei et al. ²⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Liguori et al. ⁴⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Liu et al. ¹⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ma et al. ¹³	yes	yes	Unclear	No	No	yes	yes	yes
Shang et al. ²²	Yes	yes	yes	yes	Unclear	yes	yes	yes
Sun et al. ¹⁷	Unclear	yes	Unclear	yes	Not applicable	yes	yes	yes
Sun et al. ⁴⁸	yes	yes	yes	yes	yes	yes	yes	yes
Tian et al. ¹⁸	yes	yes	yes	yes	Not applicable	yes	yes	yes
To et al. ¹⁶	no	yes	yes	yes	Not applicable	yes	yes	yes
Wang et al. ⁵⁹	yes	yes	yes	yes	yes	yes	yes	yes
Wang et al. ²⁸	yes	yes	yes	yes	Not applicable	yes	yes	yes
Wei et al. ³⁸	yes	yes	yes	yes	Not applicable	yes	yes	yes
Wu et al. ⁴	yes	yes	yes	yes	yes	yes	yes	yes
Xu et al. ⁶⁰	no	yes	yes	yes	yes	yes	yes	yes
Xu et al. ⁴⁵	yes	yes	yes	yes	Not applicable	yes	yes	yes
Yang et al. ³	No	yes	yes	yes	Not applicable	yes	yes	yes
Yang et al. ⁵	yes	yes	yes	yes	Not applicable	yes	yes	yes
Yang et al. ⁴¹	yes	yes	yes	yes	Not applicable	yes	yes	yes
Yin et al. ⁵⁴	Unclear	yes	yes	yes	Not applicable	yes	yes	yes
Yu et al. ⁶¹	unclear	yes	yes	yes	Not applicable	yes	yes	yes
Zha et al. ⁶²	unclear	yes	yes	yes	Not applicable	yes	yes	yes
Zhang et al. ¹⁵	Unclear	yes	yes	yes	Not applicable	yes	yes	yes
Zhang et al. ³¹	Unclear	yes	yes	yes	Not applicable	yes	yes	yes
Zhang et al. ³⁷	yes	yes	yes	yes	Not applicable	yes	yes	yes
Zhang et al. ⁴⁶	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Zhao et al. ⁴⁰	Yes	Yes	Yes	Yes	No	No	Yes	Yes
Zheng et al. ³⁰	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Zheng et al. ³²	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Zhou et al. ⁴²	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Zhou et al. ²⁰	yes	yes	yes	yes	Yes	Yes	yes	yes
Huang et al. ⁶⁵	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Zhang et al. ⁴⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Liu et al. ⁵⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Niu et al. ³⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Peng et al. ⁴⁴	Yes	Yes	Yes	Yes	Not applicable	Yes	Yes	Yes
Qiu et al. ⁶³	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Shabto et al. ¹⁶	Unclear	Yes	Yes	Yes	Not applicable	Yes	Yes	Unclear
Shi et al. ¹	Yes	Yes	Yes	Yes	Not applicable	Yes	Yes	Yes
Tian et al. ²⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Yan et al. ²⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

One of the limitations in this review is the concentration of studies from China, and the shortage of research from other locations in the world, due to the periodical effect of the pandemic advancement to the other locations and is also reflected in the manuscript's origin. One of the limiting points is the great variability of studies, including different populations in the sample, with different ages, with or without comorbidities, and severe, moderate, and mild complications. The fact is that at the beginning of the COVID-19 pandemic, there was a great variability of studies, and this systematic review chose to select comprehensive studies and demonstrate a general overview of how these symptoms appeared.

The selected studies did not directly evaluate the prevalence and associations between neurological symptoms and COVID-19. However, the systematic review with meta-analysis of

these findings was able to estimate the prevalence of symptoms in different localities and populations worldwide. It has relevance in raising interest in the investigation of these symptoms in the various stages of the infection by the new coronavirus.

Conclusion

The results of this systematic review with meta-analysis demonstrate the existence of neurological manifestations among the individuals affected by the new coronavirus, the presence of headache and myalgia in different severity stages, and the diversity of the populations investigated. Therefore, it is suggested to deepen the findings in novel studies with the theme and to investigate the symptoms associated with the severity of the cases, as well as the stage after the disease.

REFERENCES

- Shi X, Lu Y, Li R, Tang Y, Shi N, Song F, et al. Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China. *J Med Virol.* 2020;92(10):1922-31. <https://doi.org/10.1002/jmv.25893>
- Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. *J Intern Med.* 2020;288(3):335-44. <https://doi.org/10.1111/joim.13089>
- Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Analysis of 92 deceased patients with COVID-19. *J Med Virol.* 2020;92(11):2511-15. <https://doi.org/10.1002/jmv.25891>
- Wei XS, Wang XR, Zhang JC, Yang WB, Ma WL, Yang BH, et al. A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2. *J Microbiol Immunol Infect.* 2021;54(1):54-60. <https://doi.org/10.1016/j.jmii.2020.04.013>
- Yang P, Wang P, Song Y, Zhang A, Yuan G, Cui Y. A retrospective study on the epidemiological characteristics and establishment of an early warning system of severe COVID-19 patients. *J Med Virol.* 2020;92(10):2173-80. <https://doi.org/10.1002/jmv.26022>
- Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ.* 2020;368:m1091. <https://doi.org/10.1136/bmj.m1091>
- Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc.* 2015;13(3):147-53. <https://doi.org/10.1097/XEB.0000000000000054>
- Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. *J Epidemiol Community Health.* 2013;67(11):974-8. <https://doi.org/10.1136/jech-2013-203104>
- Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health.* 2019;22(4):153-60. <https://doi.org/10.1136/ebmental-2019-300117>
- Giacomelli A, Ridolfo AL, Milazzo L, Oreni L, Bernacchia D, Siano M, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. *Pharmacol Res.* 2020;158:104931. <https://doi.org/10.1016/j.phrs.2020.104931>
- Han YN, Feng ZW, Sun LN, Ren XX, Wang H, Xue YM, et al. A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults. *J Med Virol.* 2020;92(9):1596-602. <https://doi.org/10.1002/jmv.25835>
- Lei Z, Cao H, Jie Y, Huang Z, Guo X, Chen J, et al. A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. *Travel Med Infect Dis.* 2020;35:101664. <https://doi.org/10.1016/j.tmaid.2020.101664>
- Ma H, Hu J, Tian J, Zhou X, Li H, Laws MT, et al. A single-center, retrospective study of COVID-19 features in children: a descriptive investigation. *BMC Med.* 2020;18:123. <https://doi.org/10.1186/s12916-020-01596-9>
- Liu Z, Jin C, Wu CC, Liang T, Zhao H, Wang Y, et al. Association between Initial Chest CT or Clinical Features and Clinical Course in Patients with Coronavirus Disease 2019 Pneumonia. *Korean J Radiol.* 2020;21(6):736-45. <https://doi.org/10.3348/kjr.2020.0171>
- Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, et al. Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study. *Diabetes Res Clin Pract.* 2020;165:108227. <https://doi.org/10.1016/j.diabres.2020.108227>
- Shabto JM, Loerinc L, O'Keefe GA, O'Keefe J. Characteristics, and outcomes of COVID-19 positive patients with diabetes managed as outpatients. *Diabetes Res Clin Pract.* 2020;164:108229. <https://doi.org/10.1016/j.diabres.2020.108229>
- Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. *J Autoimmun.* 2020;112:102473. <https://doi.org/10.1016/j.jaut.2020.102473>

18. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. *J Infect.* 2020;80(4):401-6. <https://doi.org/10.1016/j.jinf.2020.02.018>
19. Ji M, Yuan L, Shen W, Lv J, Li Y, Lu X, et al. Characteristics of disease progress in patients with coronavirus disease 2019 in Wuhan, China. *Epidemiol Infect.* 2020;148:e94. <https://doi.org/10.1017/S0950268820000977>
20. Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. *Clin Transl Sci.* 2020;13(6):1077-86. <https://doi.org/10.1111/cts.12805>
21. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020;130(5):2620-9. <https://doi.org/10.1172/JCI137244>
22. Shang Y, Xu C, Jiang F, Huang R, Li Y, Zhou Y, et al. Clinical characteristics and changes of chest CT features in 307 patients with common COVID-19 pneumonia infected SARS-CoV-2: A multicenter study in Jiangsu, China. *Int J Infect Dis.* 2020;96:157-62. <https://doi.org/10.1016/j.ijid.2020.05.006>
23. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics, and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet.* 2020;395(10226):809-15. [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3)
24. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics, and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. *EClinicalMedicine.* 2020;21:100331. <https://doi.org/10.1016/j.eclinm.2020.100331>
25. D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics, and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. *Ann Rheum Dis.* 2020;79(9):1156-62. <https://doi.org/10.1136/annrheumdis-2020-217888>
26. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics, and outcomes of patients with severe COVID-19 with diabetes. *BMJ Open Diabetes Res Care.* 2020;8(1):e001343. <https://doi.org/10.1136/bmjdr-2020-001343>
27. Tian S, Chang Z, Wang Y, Wu M, Zhang W, Zhou G, et al. Clinical Characteristics and Reasons for Differences in Duration from Symptom Onset to Release from Quarantine Among Patients With COVID-19 in Liaocheng, China. *Front Med (Lausanne).* 2020;7:210. <https://doi.org/10.3389/fmed.2020.00210>
28. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061-9. <https://doi.org/10.1001/jama.2020.1585>
29. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, et al. Clinical characteristics of 145 patients with coronavirus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. *Infection.* 2020;48(4):543-51. <https://doi.org/10.1007/s15010-020-01432-5>
30. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of coronavirus disease 2019 (COVID-19) in Changsha. *Eur Rev Med Pharmacol Sci.* 2020;24(6):3404-10. https://doi.org/10.26355/eurrev_202003_20711
31. Zhang H, Shang W, Liu Q, Zhang X, Zheng M, Yue M. Clinical characteristics of 194 cases of COVID-19 in Huanggang and Taian, China. *Infection.* 2020;48(5):687-94. <https://doi.org/10.1007/s15010-020-01440-5>
32. Zheng Y, Sun LJ, Xu M, Pan J, Zhang YT, Fang XL, et al. Clinical characteristics of 34 COVID-19 patients admitted to the intensive care unit in Hangzhou, China. *J Zhejiang Univ Sci B.* 2020;21(5):378-87. <https://doi.org/10.1631/jzus.B2000174>
33. Chu J, Yang N, Wei Y, Yue H, Zhang F, Zhao J, et al. Clinical characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China. *J Med Virol.* 2020;92(7):807-13. <https://doi.org/10.1002/jmv.25793>
34. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. *Clin Microbiol Infect.* 2020;26(7):948.e1-948.e3. <https://doi.org/10.1016/j.cmi.2020.04.040>
35. Colaneri M, Sacchi P, Zuccaro V, Biscarini S, Sachs M, Roda S, et al. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. *Euro Surveill.* 2020;25(16):2000460. <https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000460>
36. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;382(18):1708-20. <https://doi.org/10.1056/NEJMoa2002032>
37. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Ann Oncol.* 2020;31(7):894-901. <https://doi.org/10.1016/j.annonc.2020.03.296>
38. Wang X, Fang J, Zhu Y, Chen L, Ding F, Zhou R, et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. *Clin Microbiol Infect.* 2020;26(8):1063-8. <https://doi.org/10.1016/j.cmi.2020.03.032>
39. Niu S, Tian S, Lou J, Kang X, Zhang L, Lian H, et al. Clinical characteristics of older patients infected with COVID-19: A descriptive study. *Arch Gerontol Geriatr.* 2020;89:104058. <https://doi.org/10.1016/j.archger.2020.104058>
40. Zhao XY, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. *BMC Infect Dis.* 2020;20:311. <https://doi.org/10.1186/s12879-020-05010-w>
41. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course, and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* 2020;8(5):475-81. [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5)
42. Zhou F, Yu T, Du R, Shu H, Xia J, Liu H, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in *Lancet*. *Lancet.* 2020;395(10229):1054-62. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
43. Kato H, Shimizu H, Shibue Y, Hosoda T, Iwabuchi K, Nagamine K, et al. The clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship. *J Infect Chemother.* 2020;26(8):865-9. <https://doi.org/10.1016/j.jiac.2020.05.005>
44. Peng S, Huang L, Zhao B, Zhou S, Braithwaite I, Zhang N, et al. Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis. *J Thorac Cardiovasc Surg.* 2020;160(2):585-92.e2. <https://doi.org/10.1016/j.jtcvs.2020.04.005>

45. Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, et al. Clinical features, and dynamics of viral load in imported and non-imported patients with COVID-19. *Int J Infect Dis.* 2020;94:68-71. <https://doi.org/10.1016/j.ijid.2020.03.022>
46. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features, and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. *J Clin Virol.* 2020;127:104364. <https://doi.org/10.1016/j.jcv.2020.104364>
47. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
48. Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. *J Autoimmun.* 2020;112:102473. <https://doi.org/10.1016/j.jaut.2020.102473>
49. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. *Brain Behav Immun.* 2020;88:11-16. <https://doi.org/10.1016/j.bbi.2020.05.037>
50. Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva AA, Borchers N, et al. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak. *Pediatr Allergy Immunol.* 2020;31(7):841-7. <https://doi.org/10.1111/pai.13278>
51. Kardeş S, Erdem A, Gürdal H. Public interest in musculoskeletal symptoms and disorders during the COVID-19 pandemic: Infodemiology study. *Z Rheumatol.* 2022;81(3):247-52. <https://doi.org/10.1007/s00393-021-00989-2>
52. Cortez KJC, Demot BA, Bartolo SS, Feliciano DD, Ciriaco VMP, Labi IIE, et al. Clinical characteristics and outcomes of COVID-19 patients in a tertiary hospital in Baguio City, Philippines. *Western Pac Surveill Response J.* 2021;12(4):1-11. <https://doi.org/10.5365/wpsar.2021.12.4.852>
53. He X, Cheng X, Feng X, Wan H, Chen S, Xiong M, et al. Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in China: A Meta-Analysis. *Front Public Health.* 2021;8:561264. <https://doi.org/10.3389/fpubh.2020.561264>
54. Yin R, Feng W, Wang T, Chen G, Wu T, Chen D, et al. Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019. *J Med Virol.* 2020;92(10):1782-4. <https://doi.org/10.1002/jmv.25888>
55. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet.* 2020;395(10239):1763-70. [https://doi.org/10.1016/S0140-6736\(20\)31189-2](https://doi.org/10.1016/S0140-6736(20)31189-2)
56. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterization Protocol: prospective observational cohort study. *BMJ.* 2020;369:m1985. <https://doi.org/10.1136/bmj.m1985>
57. Du N, Chen H, Zhang Q, Che L, Lou L, Li X, et al. A case series describing the epidemiology and clinical characteristics of COVID-19 infection in Jilin Province. *Virulence.* 2020;11(1):482-5. <https://doi.org/10.1080/21505594.2020.1767357>
58. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl).* 2020;133(9):1025-31. <https://doi.org/10.1097/CM9.0000000000000744>
59. To KLA, Fok YYY. Homeopathic Clinical Features of 18 Patients in COVID-19 Outbreaks in Hong Kong. *Homeopathy.* 2020;109(3):146-62. <https://doi.org/10.1055/s-0040-1710545>
60. Wu X, Liu L, Jiao J, Yang L, Zhu B, Li X. Characterization of clinical, laboratory and imaging factors related to mild vs. severe covid-19 infection: a systematic review and meta-analysis. *Ann Med.* 2020;52(7):334-44. <https://doi.org/10.1080/07853890.2020.1802061>
61. Yu Z, Wu H, Huang Q, Zhong Z. Clinical and biochemical indexes of 11 COVID-19 patients and the genome sequence analysis of the tested SARS-CoV-2. *J Clin Lab Anal.* 2021;35(12):e24088. <https://doi.org/10.1002/jcla.24088>
62. Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Med J Aust.* 2020;212(9):416-20. <https://doi.org/10.5694/mja2.50577>
63. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis.* 2020;20(6):689-96. [https://doi.org/10.1016/S1473-3099\(20\)30198-5](https://doi.org/10.1016/S1473-3099(20)30198-5)
64. Alberici F, Delbarba E, Manenti C, et al. A single-center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. *Kidney Int.* 2020;97(6):1083-8. <https://doi.org/10.1016/j.kint.2020.04.002>
65. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ.* 2020;368:m606. <https://doi.org/10.1136/bmj.m606>
66. Yıldız Y, Şahin BÖ, Demir MC, Demir Ş, Çiftci B, Köktürk N, et al. Risk factors for post-acute sequelae of COVID-19 in hospitalized patients: An observational study based on a survey in a tertiary care center in Türkiye. *Tuberk Toraks.* 2023;71(3):261-72. <https://doi.org/10.5578/tt.20239707>
67. Hägglöf E, Bell M, Zettersten E, Engerström L, Larsson E. Long-term survival after intensive care for COVID-19: a nationwide cohort study of more than 8000 patients. *Ann Intensive Care.* 2023;13(1):76. <https://doi.org/10.1186/s13613-023-01156-3>
68. Patel UK, Mehta N, Patel A, Patel N, Ortiz JF, Khurana M, et al. Long-Term Neurological Sequelae Among Severe COVID-19 Patients: A Systematic Review and Meta-Analysis. *Cureus.* 2022;14(9):e29694. <https://doi.org/10.7759/cureus.29694>
69. Rocha-Filho PAS. Headache is associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management. *Headache.* 2022;62(6):650-6. <https://doi.org/10.1111/head.14319>
70. Ribeiro DE, Oliveira-Giacomelli Á, Glaser T, Arnaud-Sampaio VF, Andrejew R, Dieckmann L, et al. Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. *Mol Psychiatry.* 2021;26:1044-59. <https://doi.org/10.1038/s41380-020-00965-3>